Inloggen

Login
 
Wachtwoord vergeten?

Galapagos 200 euro per aandeel

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
848 Posts, Pagina: « 1 2 3 4 5 6 ... 38 39 40 41 42 43 | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
inspirator
0
GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION

Terms of the Collaboration

Galapagos will fund and lead all discovery and development autonomously until the end of Phase 2. After the completion of a qualifying Phase 2 study, Gilead will have the option to acquire an expanded license to the compound. If the option is exercised, Gilead and Galapagos will co-develop the compound and share costs equally. Gilead will maintain option rights to Galapagos' programs through the 10-year term of the collaboration and for up to an additional three years thereafter for those programs that have entered clinical development prior to the end of the collaboration term.

If GLPG1690 is approved in the United States, Gilead will pay Galapagos an additional $325 million milestone fee.

For GLPG1972, Gilead has the option to pay a $250 million fee to license the compound in the United States after the completion of the ongoing Phase 2b study in osteoarthritis. If certain secondary efficacy endpoints are met, Gilead would pay up to an additional $200 million. Following opt in, Galapagos would be eligible to receive up to $550 million in regulatory and commercial milestones.

For all other programs resulting from the collaboration, Gilead will make a $150 million opt-in payment per program and will owe no subsequent milestones. Galapagos will receive tiered royalties ranging from 20-24% on net sales of all Galapagos products licensed by Gilead as part of the agreement.

Filgotinib Collaboration

Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib, the experimental compound being advanced for rheumatoid arthritis and other inflammatory diseases. The companies have recently completed the comprehensive Phase 3 FINCH program in rheumatoid arthritis and plan to seek regulatory approval for the medicine in the United States and Europe before the end of the year. Under the amended agreement, Galapagos will have greater involvement in filgotinib's global strategy and participate more broadly in the commercialization of the product in Europe, providing the opportunity to build a commercial presence on an accelerated timeline.

Gilead and Galapagos will co-commercialize filgotinib in France, Germany, Italy, Spain and the United Kingdom and retain the 50/50 profit share in these countries that was part of the original filgotinib license agreement, and under the revised agreement, Galapagos will have an expanded commercial role. Galapagos retains exclusive rights in Belgium, the Netherlands and Luxembourg. The companies will share future global development costs for filgotinib equally, in lieu of the 80/20 cost split provided by the original agreement. Other terms of the original license agreement remain in effect, including the remaining $1.27 billion in total potential milestones and tiered royalties ranging from 20-30% payable in territories outside of Belgium, France, Germany, Italy, Luxembourg, the Netherlands, Spain and the United Kingdom.

Terms of the Equity Investment

Gilead's equity investment will consist of a subscription for new Galapagos shares at a price of €140.59 per share, representing a 20% premium to Galapagos' 30-day, volume-weighted average price. This will increase Gilead's stake in Galapagos from approximately 12.3% to 22% of the issued and outstanding shares in Galapagos. In addition, Galapagos intends to seek shareholder approval to issue two warrants allowing Gilead to further increase its ownership of Galapagos to up to 29.9% of the company's issued and outstanding shares. The agreement also includes a 10-year standstill restricting Gilead's ability to seek to acquire Galapagos or increase its stake in Galapagos beyond 29.9% of the company's issued and outstanding shares, subject to limited exceptions.

The transaction, which is expected to close late in the third quarter of 2019, is subject to certain closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and receipt of merger control approval from the Austrian Federal Competition Authority.

Barclays, Centerview Partners and Lazard are acting as financial advisors to Gilead. Moelis & Co. and Morgan Stanley are acting as financial advisors to Galapagos. Skadden, Arps, Slate, Meagher & Flom, Covington & Burling LLP and Eubelius are serving as legal counsel to Gilead and Baker McKenzie and Linklaters are serving as legal counsel to Galapagos.

This press release contains inside information with respect to GALAPAGOS within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).
inspirator
0
Koers Galapagos naar 200 euro; zelfs 210 euro.

4,5 miljard euro
MEGABEDRAG
Galapagos ontvangt, dankzij het voorschot en de aandelentransactie, een megabedrag van 4,5 miljard euro. Aan de slotkoers van afgelopen vrijdag, 128 euro, komt dat neer op 82 euro extra cash per aandeel.

www.tijd.be/ondernemen/farma-biotech/...
Dicall69
0
quote:

inspirator schreef op 14 jul 2019 om 22:15:


Koers Galapagos naar 200 euro; zelfs 210 euro.

4,5 miljard euro
MEGABEDRAG
Galapagos ontvangt, dankzij het voorschot en de aandelentransactie, een megabedrag van 4,5 miljard euro. Aan de slotkoers van afgelopen vrijdag, 128 euro, komt dat neer op 82 euro extra cash per aandeel.

www.tijd.be/ondernemen/farma-biotech/...



Je kunt deze deal niet anders dan als ongekend positief beoordelen dat gaat morgen een klapper worden, denk aan een stijging van 15 tot 25 % !!!
inspirator
0
De eerste profs zien inmiddels ook het allang beoogde koersdoel Galapagos, door de particulier.

Koersdoel Galapagos 200 euro; nog dit jaar.

Op lange termijn koersdoel zelfs 400 euro (binnen 10 jaar).

m.youtube.com/watch?v=hXf-sIjVNlg



inspirator
0
Galapagos is de parel van de beurs.

Onno vd Stolpe stelt dat Galapagos over 10 jaar wellicht groter is als Gilead.

Koerspotentieel Galapagos =. 3000 euro per aandeel

www.bnr.nl/nieuws/gezondheid/10384186...
inspirator
0
quote:

inspirator schreef op 15 jul 2019 om 20:36:


Galapagos is de parel van de beurs.

Onno vd Stolpe stelt dat Galapagos over 10 jaar wellicht groter is als Gilead.

Koerspotentieel Galapagos =. 3000 euro per aandeel

www.bnr.nl/nieuws/gezondheid/10384186...




Galapagos: the sky is the limit.
inspirator
0
quote:

inspirator schreef op 15 jul 2019 om 20:36:


Galapagos is de parel van de beurs.

Onno vd Stolpe stelt dat Galapagos over 10 jaar wellicht groter is als Gilead.

Koerspotentieel Galapagos =. 3000 euro per aandeel

www.bnr.nl/nieuws/gezondheid/10384186...




Koersreactie Galapagos wel erg lauw.
848 Posts, Pagina: « 1 2 3 4 5 6 ... 38 39 40 41 42 43 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Galapagos Meer »

Koers 153,200   Verschil +1,00 (+0,66%)
Laag 150,700   Volume 447.474
Hoog 153,300   Gem. Volume 798.422
16-jul-19 14:16
label premium

Galapagos: Gilead gaat all-in

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium